Cynthia Kohl1, Thiha Aung2,3, Silke Haerteis2, Atanas Ignatov4, Olaf Ortmann5, Thomas Papathemelis6. 1. Department of Gynecology and Obstetrics, St. Marien Hospital Amberg, 92224, Amberg, Germany. kohl.cynthia@gmail.com. 2. Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053, Regensburg, Germany. 3. Faculty of Applied Healthcare Science, Deggendorf Institute of Technology, 94469, Deggendorf, Germany. 4. Department of Gynecology and Obstetrics, University Hospital Magdeburg, 39120, Magdeburg, Germany. 5. Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany. 6. Department of Gynecology and Obstetrics, St. Marien Hospital Amberg, 92224, Amberg, Germany.
Abstract
PURPOSE: We aimed to evaluate the role of the chorioallantoic membrane model (CAM) in breast cancer research. METHODS: The following is an overview of the use of the CAM in the field of breast cancer research based on a PubMed literature query. RESULTS: The CAM is a 3D in vivo model that can be used for the analysis of tumor growth, biology and angiogenesis of primary tumor tissue or tumor cell lines. The CAM model has been used in breast cancer research for drug testing, migration assays and the evaluation of vascularization, amongst others. The CAM model is a valuable method that offers a better imitation of the physiological phenomena compared to 2D or 3D in vitro models. CONCLUSION: The CAM model has primarily and successfully been utilized for the assessment of the tumor biology of established breast cancer cell lines. Further, the CAM model is a promising method to analyze patient derived primary tumor material and could be used as a "patient-specific 3D-tumor-therapy-model" for the cost-efficient evaluation of anti-cancer drugs to find the optimal treatment for breast cancer patients.
PURPOSE: We aimed to evaluate the role of the chorioallantoic membrane model (CAM) in breast cancer research. METHODS: The following is an overview of the use of the CAM in the field of breast cancer research based on a PubMed literature query. RESULTS: The CAM is a 3D in vivo model that can be used for the analysis of tumor growth, biology and angiogenesis of primary tumor tissue or tumor cell lines. The CAM model has been used in breast cancer research for drug testing, migration assays and the evaluation of vascularization, amongst others. The CAM model is a valuable method that offers a better imitation of the physiological phenomena compared to 2D or 3D in vitro models. CONCLUSION: The CAM model has primarily and successfully been utilized for the assessment of the tumor biology of established breast cancer cell lines. Further, the CAM model is a promising method to analyze patient derived primary tumor material and could be used as a "patient-specific 3D-tumor-therapy-model" for the cost-efficient evaluation of anti-cancer drugs to find the optimal treatment for breast cancer patients.
Authors: Oliver Baum; Ruslan Hlushchuk; Andrea Forster; Richard Greiner; Philipp Clézardin; Yingshe Zhao; Valentin Djonov; Günther Gruber Journal: Int J Oncol Date: 2007-02 Impact factor: 5.650
Authors: Maggie C U Cheang; Miguel Martin; Torsten O Nielsen; Aleix Prat; David Voduc; Alvaro Rodriguez-Lescure; Amparo Ruiz; Stephen Chia; Lois Shepherd; Manuel Ruiz-Borrego; Lourdes Calvo; Emilio Alba; Eva Carrasco; Rosalia Caballero; Dongsheng Tu; Kathleen I Pritchard; Mark N Levine; Vivien H Bramwell; Joel Parker; Philip S Bernard; Matthew J Ellis; Charles M Perou; Angelo Di Leo; Lisa A Carey Journal: Oncologist Date: 2015-04-23
Authors: Elina Azenshtein; Galia Luboshits; Sima Shina; Eran Neumark; David Shahbazian; Miguel Weil; Nely Wigler; Iafa Keydar; Adit Ben-Baruch Journal: Cancer Res Date: 2002-02-15 Impact factor: 12.701
Authors: Iman W Achkar; Sara Kader; Shaima S Dib; Kulsoom Junejo; Salha Bujassoum Al-Bader; Shahina Hayat; Aditya M Bhagwat; Xavier Rousset; Yan Wang; Jean Viallet; Karsten Suhre; Anna Halama Journal: Metabolites Date: 2020-06-28
Authors: James M Arnold; Franklin Gu; Chandrashekar R Ambati; Uttam Rasaily; Esmeralda Ramirez-Pena; Robiya Joseph; Mohan Manikkam; Rebeca San Martin; Christy Charles; Yinghong Pan; Sujash S Chatterjee; Petra Den Hollander; Weijie Zhang; Chandandeep Nagi; Andrew G Sikora; David Rowley; Nagireddy Putluri; Xiang H-F Zhang; Balasubramanyam Karanam; Sendurai A Mani; Arun Sreekumar Journal: Oncogene Date: 2019-07-15 Impact factor: 9.867
Authors: Konstantin Drexler; Barbara Schwertner; Silke Haerteis; Thiha Aung; Mark Berneburg; Edward K Geissler; Maria E Mycielska; Sebastian Haferkamp Journal: Cancers (Basel) Date: 2022-07-14 Impact factor: 6.575